Mary Rinella to Biomarkers
This is a "connection" page, showing publications Mary Rinella has written about Biomarkers.
Connection Strength
0.716
-
Pioneering the path to NASH biomarker approval. Nat Med. 2023 10; 29(10):2416-2417.
Score: 0.127
-
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 10; 71(4):823-833.
Score: 0.094
-
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol. 2019 04; 114(4):579-590.
Score: 0.093
-
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
Score: 0.091
-
Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
Score: 0.081
-
Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
Score: 0.071
-
Phosphatidylethanol in steatotic liver disease. J Hepatol. 2025 Nov; 83(5):1189-1203.
Score: 0.036
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
Score: 0.027
-
From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021 03; 73(3):1194-1198.
Score: 0.026
-
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 12 14; 394(10215):2184-2196.
Score: 0.024
-
Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2019 05; 114(5):758-763.
Score: 0.023
-
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
Score: 0.022